flow study semaglutide 🔴Cardiovascular outcomes with by severity of chronic kidney disease in type 2 diabetes: the trial⤵️ 🔹Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants FLOW Trial: Semaglutide Lowers Risk

doi: 10.1016/j.jconrel.2024.01.030

Stephen Childs, a senior lecturer in pharmaceutical chemistry, said: "There's a massive discrepancy in the amount of this drug in the products people are purchasing

The SELECT trial showed that semaglutide reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in adults with obesity and established cardiovascular disease, without requiring a diabetes diagnosis. The FLOW trial showed kidney benefits with semaglutide use in patients with type 2 diabetes and chronic kidney disease. Improvements in hard clinical outcomes like cardiac events, kidney disease, and death are commonly observed with GLP-1 use, and are due to both the direct effects of treating the obesity, and indirect effects of the medications themselves

Omega-3, omega-6, and other essential fatty acids influence inflammation, cardiovascular health, cognition, and healthy aging

slim, but having very little muscle mass/tone

No subtle irritation